Concentrations of doxorubicin, cyclophosphamide, and rituximab in plasma and CSF samples
| Drug concentrations . | Without NGR-hTNF* . | After NGR-hTNF† . | P . |
|---|---|---|---|
| Plasma | |||
| Doxorubicin, ng/mL | 29.6 ± 7.4 | 26.0 ± 6.7 | .43 |
| Cyclophosphamide, mg/L | 26.3 ± 7.7 | 27.8 ± 7.9 | .17 |
| Rituximab, ng/mL | 45.4 ± 17.0 | 69.1 ± 13.4 | .04 |
| CSF | |||
| Doxorubicin, ng/mL | <2.5 (all samples) | <2.5 (all samples) | |
| Cyclophosphamide, mg/L | 14.1 ± 3.5 | 15.5 ± 4.8 | .27 |
| Rituximab, ng/mL | <1.0 (all samples) | <1.0 (all samples) | |
| CSF/plasma ratio‡ | |||
| Cyclophosphamide, % | 60 ± 20 | 62 ± 19 | .73 |
| Drug concentrations . | Without NGR-hTNF* . | After NGR-hTNF† . | P . |
|---|---|---|---|
| Plasma | |||
| Doxorubicin, ng/mL | 29.6 ± 7.4 | 26.0 ± 6.7 | .43 |
| Cyclophosphamide, mg/L | 26.3 ± 7.7 | 27.8 ± 7.9 | .17 |
| Rituximab, ng/mL | 45.4 ± 17.0 | 69.1 ± 13.4 | .04 |
| CSF | |||
| Doxorubicin, ng/mL | <2.5 (all samples) | <2.5 (all samples) | |
| Cyclophosphamide, mg/L | 14.1 ± 3.5 | 15.5 ± 4.8 | .27 |
| Rituximab, ng/mL | <1.0 (all samples) | <1.0 (all samples) | |
| CSF/plasma ratio‡ | |||
| Cyclophosphamide, % | 60 ± 20 | 62 ± 19 | .73 |
Samples collected after the first course of treatment (ie, after R-CHOP without NGR-hTNF).
Samples collected after the second course of treatment (ie, after NGR-hTNF followed by R-CHOP).
The ratio was not estimated for doxorubicin and rituximab because CSF concentrations resulted below the lower limit of quantification.